2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3544 Ultra-low-dose mosunetuzumab for indolent B cell lymphoma: Exploring the boundaries of bispecific antibody therapy

Mengyang Di, MD, PhD, Carrie Ho, MD2, Paul S Martin, MD3, Brian G Till, MD4, Vikram Raghunathan, MD5, Kristi Matsumura6, Ted Gooley, PhD7, Kevin Ng, MS8, Christopher Mejias9, Angela Rieger10, Alireza Ghodsi11, Delphine Chen12, Taran Gujral, PhD13, Stephen Douglas Smith, MD14, Ajay Gopal, MD15
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 UCSF, San Fransisco, California, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 University of Washington, Seattle, Washington, United States
10 University of Washington, Seattle, Washington, United States
11 University of Washington, Seattle, Washington, United States
12 University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background:

The CD20-directed CD3 T-cell engager mosunetuzumab (mosun) is highly active in treatment-naïve (TN) follicular lymphoma (FL) including those with high tumor burden (HTB) by GELF criteria (Lynch ASH 2025, Falchi ASH 2025, Flinn ASCO 2025). Mosun is also being explored in the important SWOG 2308 trial that compares full-dose mosun and rituximab for low tumor burden (LTB) FL (NCT06337318).

 

Given the lack of a clear dose-response effect with other immunotherapeutics (reviewed in Sun J Immunother Cancer, Vanita Noronha JCO 2026), the observation of responses with bispecifics at very low dose levels from the phase I mosun trial (Budde JCO 2021), and anecdotal responses observed during step-up dosing, we hypothesized that ultra-low-dose mosun could be effective in TN LTB indolent B-NHL. We also predicted that this approach would lead to lower toxicity. Here we present the initial prespecified interim analysis of ultra-low-dose mosun in TN LTB indolent B-NHL (NCT06442475).

 

Methods: In this pilot trial, we enrolled adult patients with TN FL or marginal zone lymphoma (MZL) with LTB defined by GELF criteria. Participants received IV mosun in 4 weekly doses: 1 mg on D1, 2 mg on D8, 1 mg on D15, and 1 mg on D21 (total, 5 mg). The primary endpoint was best overall response (OR, including CR and PR) by PET and diagnostic CT scans during week 13 per Lugano criteria.  Target enrollment was 20 patients in a two-stage design, where ≥4 responses among the first 10 patients allowed for enrollment of the remaining 10 patients. We represents here this pre-planned interim analysis.  T cell subsets, microbiome, cytokine profile, and minimal residual disease (MRD) samples were analyzed to explore correlations with efficacy and safety in exploratory analyses

 

Results: We enrolled 10 patients (7 FL and 3 MZL) between 8/2024 and 3/2026, with all participants evaluable for safety and efficacy. The median age was 57 years (range: 37-65), 10% were men, and 90% were White. All but one patient had an intermediate- to high-risk FLIPI score, the median disease bulk was 2.85 cm (range: 1.9-3.9), and metabolic tumor volume (MTV) was 65.5 ml (range: 7.7-259). 20% met GELF definition criteria based on symptomatic disease. Although all patients were determined to meet LTB by GELF criteria at enrollment, one patient had three lesions at least 3 cm (HTB) based on a retrospective radiology review during data analyses.

 

All 10 participants completed planned therapy with OR rate (ORR) and CR rate of 50% and 30%. Among 8 with FDG avid disease at baseline, the OR rate (ORR) and CR rate were 62.5% and 37.5%, based on metabolic response by PET; the medan decrease in MTV was 56.9 ml at week 13 (P < 0.01), 87.5% and 62.5% had any decrease and ≥50% reduction in MTV.  Two participants (20%) received additional therapy (rituximab in 1, bendamustine/rituximab in 1) after completion of the trial due to preference of treating physicians/patients. One met GELF criteria based on symptoms at treatment initiation outside the trial; neither had evidence of radiographic progression. After a median follow-up of 11.4 months, 12-month PFS was 100%.

 

There were no serious adverse events (AEs) observed on this trial.  Three patients had cytokine release syndrome (2 grade 1, one grade 2). Other notable AEs included headache in 7/10, rash in 5, and fatigue and AST/ALT elevation in 3 patients each. Only 1 pt experienced an infection (urinary tract infection, grade 2).

 

Flow cytometry showed that all 10 participants had B-cell aplasia in the blood on C1D15 and remained B-cell depleted at week 13 of starting the trial treatment. We observed a transient increase in T cell exhaustion and activation markers at C1D15, which decreased to baseline during week 13. The analyses of cytokine profiles, microbiome, and MRD are on-going; results will be reported in the future.

 

Conclusions: Ultra-low-dose mosun (a total of 5 mg) appears to achieve durable B-cell aplasia and responses including CR in TN LTB indolent B-NHL with a very favorable safety profile. Longer follow-up and a larger sample size is planned  to further examine the potential of delaying toxic chemoimmunotherapy using ultra-low-dose mosun in this population. Results from this study may lead to optimized dosing of bisepecific antibodies for LTB and low risk diseases, with potential implications for resource utilization and broadening access to therapy.
Mengyang Di, MD, PhD: Merck - Honoraria; Eli Lilly - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Regeneron - Research Funding; Schrodinger - Research Funding; Dren Bio - Research Funding; Incyte Corporation - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)